Authors: Moyo, S.1; Verver, S.2; Hawkridge, A.3; Geiter, L.4; Hatherill, M.1; Workman, L.5; Ontong, C.1; Msemburi, W.1; Tameris, M.1; Geldenhuys, H.1; Mulenga, H.1; Snowden, M. A.6; Hanekom, W. A.1; Hussey, G.3; Mahomed, H.1; South African Tuberculosis Vaccine Initiative Neonatal Study Team
Source: The International Journal of Tuberculosis and Lung Disease, Volume 16, Number 2, 1 February 2012, pp. 185-191(7)
Document Type: Research Article
Affiliations: 1: South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine & School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa 2: KNCV Tuberculosis Foundation, The Hague, The Netherlands; CINIMA, Academic Medical Centre, Amsterdam, The Netherlands 3: Faculty of Health Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa 4: Otsuka Pharmaceutical Development and Commercialization Inc, Princeton, New Jersey, USA; Aeras Global Tuberculosis Vaccine Foundation, Rockville, Maryland, USA 5: Pharmacology Department, University of Cape Town, Cape Town, South Africa 6: Aeras Global Tuberculosis Vaccine Foundation, Rockville, Maryland, USA
Publication date: February 1, 2012
The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.
Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website